181 related articles for article (PubMed ID: 34863177)
1. Eribulin activity in soft tissue sarcoma monolayer and three-dimensional cell line models: could the combination with other drugs improve its antitumoral effect?
Escudero J; Heredia-Soto V; Wang Y; Ruiz P; Hu Y; Gallego A; Pozo-Kreilinger JJ; Martinez-Marin V; Berjon A; Ortiz-Cruz E; Bernabeu D; Feliu J; Tang J; Redondo A; Mendiola M
Cancer Cell Int; 2021 Dec; 21(1):646. PubMed ID: 34863177
[TBL] [Abstract][Full Text] [Related]
2. Eribulin in Patients with Liposarcoma and Leiomyosarcoma: A Retrospective Single-Center Experience.
Steinbrecher O; Brodowicz T; Raderer M; Scharrer A; Fabsits J; Lamm W
Oncology; 2023; 101(2):89-95. PubMed ID: 36273457
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Eribulin Plus Gemcitabine Combination in L-Sarcomas.
López-Álvarez M; González-Aguilera C; Moura DS; Sánchez-Bustos P; Mondaza-Hernández JL; Martín-Ruiz M; Renshaw M; Ramos R; Castilla C; Blanco-Alcaina E; Hindi N; Martín-Broto J
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614121
[TBL] [Abstract][Full Text] [Related]
4. Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates.
Haddox CL; Nathenson MJ; Mazzola E; Lin JR; Baginska J; Nau A; Weirather JL; Choy E; Marino-Enriquez A; Morgan JA; Cote GM; Merriam P; Wagner AJ; Sorger PK; Santagata S; George S
Clin Cancer Res; 2024 Apr; 30(7):1281-1292. PubMed ID: 38236580
[TBL] [Abstract][Full Text] [Related]
5. Eribulin in advanced liposarcoma and leiomyosarcoma.
Setola E; Noujaim J; Benson C; Chawla S; Palmerini E; Jones RL
Expert Rev Anticancer Ther; 2017 Aug; 17(8):717-723. PubMed ID: 28621163
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of eribulin mesylate in advanced soft tissue sarcomas.
Noujaim J; Alam S; Thway K; Jones RL
Indian J Med Paediatr Oncol; 2016; 37(3):125-30. PubMed ID: 27688604
[TBL] [Abstract][Full Text] [Related]
7. Does the Use of Peripheral Immune-Related Markers Indicate Whether to Administer Pazopanib, Trabectedin, or Eribulin to Advanced Soft Tissue Sarcoma Patients?
Shimada E; Endo M; Matsumoto Y; Tsuchihashi K; Ito M; Kusaba H; Nabeshima A; Nawata T; Maekawa A; Matsunobu T; Setsu N; Fujiwara T; Iida K; Nakagawa M; Hirose T; Kanahori M; Oyama R; Isobe T; Ariyama H; Kohashi K; Yamamoto H; Oda Y; Iwamoto Y; Akashi K; Baba E; Nakashima Y
J Clin Med; 2021 Oct; 10(21):. PubMed ID: 34768491
[TBL] [Abstract][Full Text] [Related]
8. Systemic Therapy for Soft Tissue Sarcoma: Proposals for the Optimal Use of Pazopanib, Trabectedin, and Eribulin.
Kawai A; Yonemori K; Takahashi S; Araki N; Ueda T
Adv Ther; 2017 Jul; 34(7):1556-1571. PubMed ID: 28547734
[TBL] [Abstract][Full Text] [Related]
9. [Histology-Specific Chemotherapy in Soft-Tissue Sarcomas].
Kobayashi E; Kawai A
Gan To Kagaku Ryoho; 2017 Jun; 44(6):468-472. PubMed ID: 28698435
[TBL] [Abstract][Full Text] [Related]
10. Eribulin in the management of inoperable soft-tissue sarcoma: patient selection and survival.
Thomas C; Movva S
Onco Targets Ther; 2016; 9():5619-27. PubMed ID: 27672333
[TBL] [Abstract][Full Text] [Related]
11. The clinical outcome of eribulin treatment in Japanese patients with advanced soft tissue sarcoma: a Tokai Musculoskeletal Oncology Consortium study.
Nakamura T; Tsukushi S; Asanuma K; Katagiri H; Ikuta K; Nagano A; Kozawa E; Yamada S; Shido Y; Yamada K; Kawanami K; Ishimura D; Sudo A; Nishida Y
Clin Exp Metastasis; 2019 Aug; 36(4):343-350. PubMed ID: 31209624
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of Eribulin in Soft Tissue Sarcomas.
Phillips E; Jones RL; Huang P; Digklia A
Front Pharmacol; 2022; 13():869754. PubMed ID: 35444542
[TBL] [Abstract][Full Text] [Related]
13. Differences in the efficacy and safety of eribulin in patients with soft tissue sarcoma by histological subtype and treatment line.
Nakano K; Hayakawa K; Funauchi Y; Tanizawa T; Ae K; Matsumoto S; Tomomatsu J; Ono M; Taira S; Nishizawa M; Wang X; Ohmoto A; Sato Y; Fukuda N; Urasaki T; Takahashi S
Mol Clin Oncol; 2021 Jan; 14(1):13. PubMed ID: 33282288
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy With Eribulin Following Potentially Curative Surgery in Patients With Localized Liposarcoma.
Steinbrecher O; Brodowicz T; Popov P; Lamm W
In Vivo; 2024; 38(1):385-389. PubMed ID: 38148100
[TBL] [Abstract][Full Text] [Related]
15. Identification of microRNA biomarkers for response of advanced soft tissue sarcomas to eribulin: Translational results of the EORTC 62052 trial.
Wiemer EAC; Wozniak A; Burger H; Smid M; Floris G; Nzokirantevye A; Sciot R; Sleijfer S; Schöffski P
Eur J Cancer; 2017 Apr; 75():33-40. PubMed ID: 28214655
[TBL] [Abstract][Full Text] [Related]
16. Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine.
Demetri GD; Schöffski P; Grignani G; Blay JY; Maki RG; Van Tine BA; Alcindor T; Jones RL; D'Adamo DR; Guo M; Chawla S
J Clin Oncol; 2017 Oct; 35(30):3433-3439. PubMed ID: 28854066
[TBL] [Abstract][Full Text] [Related]
17. Combination of eribulin plus AKT inhibitor evokes synergistic cytotoxicity in soft tissue sarcoma cells.
Hayasaka N; Takada K; Nakamura H; Arihara Y; Kawano Y; Osuga T; Murase K; Kikuchi S; Iyama S; Emori M; Sugita S; Hasegawa T; Takasawa A; Miyanishi K; Kobune M; Kato J
Sci Rep; 2019 Apr; 9(1):5759. PubMed ID: 30962488
[TBL] [Abstract][Full Text] [Related]
18. Preclinical activity of selinexor in combination with eribulin in uterine leiomyosarcoma.
Mittal S; Kadamberi IP; Chang H; Wang F; Kumar S; Tsaih SW; Walker CJ; Chaluvally-Raghavan P; Charlson J; Landesman Y; Pradeep S
Exp Hematol Oncol; 2023 Sep; 12(1):78. PubMed ID: 37715291
[TBL] [Abstract][Full Text] [Related]
19. The importance of treating by histological subtype in advanced soft tissue sarcoma.
Martín Broto J; Le Cesne A; Reichardt P
Future Oncol; 2017 Jan; 13(1s):23-31. PubMed ID: 27918201
[TBL] [Abstract][Full Text] [Related]
20. Phase 2 study of eribulin in patients with previously treated advanced or metastatic soft tissue sarcoma.
Kawai A; Araki N; Naito Y; Ozaki T; Sugiura H; Yazawa Y; Morioka H; Matsumine A; Saito K; Asami S; Isu K
Jpn J Clin Oncol; 2017 Feb; 47(2):137-144. PubMed ID: 28173193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
